Skip to content

A Multicenter Prospective Cohort Study on Full-Left-Full-Right Split Liver Transplantation

A Multicenter Prospective Cohort Study on Full-Left-Full-Right Split Liver Transplantation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105356
Enrollment
Unknown
Registered
2025-07-02
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Full-Left-Full-Right Split Liver Transplantation

Interventions

Full-Left- Split Liver Transplantation patient and Full-Right Split Liver Transplantation patient:None

Sponsors

Shulan(Hangzhou)Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Donor enrollment criteria Basic conditions: 1. Donor liver assessment is suitable for split transplantation and donor age = 18 years of age. Diagnosed with end-stage liver disease after clinical evaluation, meeting the indications for liver transplantation. Intended to undergo complete left and right hemiliver split liver transplantation (FR/FLSLT); 2. No obvious contraindications; 3. Other requirements: signed informed consent form and committed to complete at least 3 years of follow-up.

Exclusion criteria

Exclusion criteria: Recipient Exclusion Criteria 1.Presence of concurrent organ failure in other vital organs(such as heart,lung,kidney,etc.),with an expectation of intolerance to liver transplantation surgery; 2.Active infections that cannot be effectively controlled; 3. Malignancies exceeding the acceptable range for transplantation; 4.Undergoing multi-organ transplantation; 5.Severe psychiatric disorders or poor compliance that would preclude effective postoperative management.

Design outcomes

Primary

MeasureTime frame
Patient survival rate;Liver function(ALT,AST,Total bilirubin);Hepatic artery, hepatic vein, portal vein and biliary stenosis situation;Hepatic artery, hepatic vein, portal vein thrombosis status;Hepatic artery, hepatic vein, portal vein flow velocity status;Hepatic artery, hepatic vein, portal vein and biliary stenosis situation;

Secondary

MeasureTime frame
Blood routine ;Blood coagulation function;Kidney function;Electrolyte;Biliary tract condition;Lung condition;Cardiovascular status;Blood concentration of antirejection drugs;

Countries

China

Contacts

Public ContactYang Zhe

Shulan(Hangzhou)Hospital

yangzhe_0201730@163.com+86 158 5822 3762

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026